

10/511960

DT05 Rec'd PCT/PTO 19 OCT 2004
Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PN0222SERIAL NO.
To Be
AssignedINFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bill Clarke, et.al.FILING DATE
HerewithGROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	9858272	12-1998	WO				
	0035900	06-2000	WO				
	0040988	07-2000	WO				
	0196895	12-2001	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Akira, et.al. "Direct nuclear magnetic resonance spectroscopic analysis of (13) C-labeled antipyrine metabolites in human urine" Drug Metabolism and Disposition: The Biological Fate of Chemicals. U.S. 06-2001 vol. 29, No. 6, pages 903-907
	Koudriakova, et.al.: "In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats" The Journal of Pharmacology and Experimental Therapeutics. U.S. 12-1996, vol. 279, no. 3, pages 1300-1309
	Scott, R.J. et.al., "Determination of a "GW cocktail" of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry: RCM. England 1999 vol. 13, no. 23, pages 2305-2319
	Stevens, J.c. et.al.: "Use of the Steroid Derivative RPR 106541 in Combination with Site-directed Mutagenesis for Enhanced Cytochrome P-450 3A4 structure/function analysis" The Journal of Pharmacology and Experimental Therapeutics. US 8-1999 vol. 290, no. 2, pages 594-602
	International Search Report for PCT/NO03/001256 dated September 3, 2003
	IPER for PCT/NO03/00125 dated March 4, 2004

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.